menu
    • menu

    Company profile for Septerna

    NEW Drugs in Dev: 3
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Septerna, Inc. is a biotechnology company focused on advancing novel, oral small-molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s focusing the Native Complex™ Platform on tackling previously difficult-to-drug GPCR targets, and their small molecule drug discovery efforts have rapidly advanced, resulting in a pipeline of innovative programs. Septerna is building a pipeline o...
    Septerna, Inc. is a biotechnology company focused on advancing novel, oral small-molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s focusing the Native Complex™ Platform on tackling previously difficult-to-drug GPCR targets, and their small molecule drug discovery efforts have rapidly advanced, resulting in a pipeline of innovative programs. Septerna is building a pipeline of GPCR-targeted, oral small-molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SepternaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    250 East Grand Avenue, Suite 65 South San Francisco, CA 94080
    Telephone
    Telephone
    +1 6503383533
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://septerna.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/septernainc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Septerna to Present Preclinical Characterization of SEP-479
    Septerna to Present Preclinical Characterization of SEP-479

    08 Jun 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260608910791/en/Septerna-to-Present-Preclinical-Characterization-of-SEP-479-an-Oral-PTH1R-Agonist-for-Hypoparathyroidism-at-2026-ENDO-Annual-Meeting

    BUSINESSWIRE
    08 Jun 2026
    Share Share
    Septerna Highlights Progress & Reports Q1 Financial Results
    Septerna Highlights Progress & Reports Q1 Financial Results

    11 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/11/3292284/0/en/septerna-highlights-business-progress-and-reports-first-quarter-2026-financial-results.html

    GLOBENEWSWIRE
    11 May 2026
    Share Share
    Septerna to Present at BofA Securities Health Care Conference
    Septerna to Present at BofA Securities Health Care Conference

    05 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/05/3287631/0/en/septerna-to-present-at-bank-of-america-securities-health-care-conference.html

    GLOBENEWSWIRE
    05 May 2026
    Share Share
    Septerna Announces Initiation of Ph 1 Clinical Trial of SEP-479
    Septerna Announces Initiation of Ph 1 Clinical Trial of SEP-479

    13 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/13/3272435/0/en/Septerna-Announces-Initiation-of-Phase-1-Clinical-Trial-of-SEP-479-an-Oral-Small-Molecule-PTH1R-Agonist-for-the-Treatment-of-Hypoparathyroidism.html

    GLOBENEWSWIRE
    13 Apr 2026
    Share Share
    Septerna Highlights Pipeline, Reports Q4 2025 & FY Results
    Septerna Highlights Pipeline, Reports Q4 2025 & FY Results

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3252307/0/en/Septerna-Highlights-Pipeline-Progress-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Septerna's SEP-631 Succeeds in Phase 1 for Mast Cell Therapy
    Septerna's SEP-631 Succeeds in Phase 1 for Mast Cell Therapy

    01 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/01/3246935/0/en/Septerna-Announces-Positive-Phase-1-Data-for-SEP-631-an-Oral-MRGPRX2-NAM-for-the-Treatment-of-Mast-Cell-Driven-Diseases-and-Outlines-Initial-Phase-2-Development-Strategy.html

    GLOBENEWSWIRE
    01 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search